Researchers reveal genetic links underlying neuroendocrine pancreatic cancer

February 16, 2017 by Elisabeth Lopez, University of Melbourne
Australian researchers reveal genetic links underlying neuroendocrine pancreatic cancer
Credit: Professor Sean Grimmond

An Australian-led international research effort has revealed that genetic changes normally linked to breast, colon and ovarian cancers could also drive a rare form of pancreatic cancer.

Researchers found as many as one in five with pancreatic neuroendocrine tumours (PanNETs) had a clear predisposition for their cancers, even though they had no of the disease.

The findings, published today in the journal Nature, offer the prospect of one day being able to identify people at risk of these cancers, as well as aggressive forms of the disease, and who might respond to current or new targeted therapies.

The breakthrough is the work of researchers at the University of Melbourne, Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, The University of Queensland and the Children's Medical Research Institute, as well as European and US teams.

They carried out whole genome sequencing of tumours from 100 Australian patients recruited through the Australian Pancreatic Cancer Genome Initiative (APGI).

Study co-leader Professor Sean Grimmond, the University of Melbourne's Bertalli Chair of Cancer Medicine, said researchers were surprised to find striking similarities between the genetic drivers of PanNETs and other cancers.

"We found that the MUTYH and BRCA2 gene mutations, normally associated with colon and breast cancers, also appear to play an important role in PanNETs," Professor Grimmond said.

"This raises exciting possibilities for how we treat this disease in the future,"

Study co-leader Dr Nicola Waddell, of QIMR Berghofer, said people without a family history of cancer could still carry a faulty gene that increases their risk of developing this tumour.

"The genetic variants we've identified may help to predict how aggressive each patient's tumour is and what sort of treatment they're likely to benefit from," she said.

"In the future, patients at risk of this rare pancreatic cancer could be identifiable through genetic screening."

PanNETs account for about two per cent of the 3,000 cases of diagnosed in Australia each year.

Amber Johns of the APGI at the Garvan Institute said although patients often have a better prognosis than those with more common pancreatic cancers, this group of tumours is highly unpredictable.

"Doctors currently face the challenge of being unable to tell apart patients who would benefit from early aggressive therapy from those who might be spared harsh treatment for less invasive cancers," Ms Johns said.

She said the study data would be freely available to cancer researchers and clinicians, to build on this work.

Explore further: Pancreatic cancer is four diseases, each with new treatment possibilities

More information: Whole genome landscape of Pancreatic Neuroendocrine Tumours, Nature, nature.com/articles/doi:10.1038/nature21063

Related Stories

Pancreatic cancer is four diseases, each with new treatment possibilities

February 24, 2016
An international team led by Australian researchers has studied the genetics of pancreatic cancer, revealing it is actually four separate diseases, each with different genetic triggers and survival rates, paving the way for ...

Study reveals new genetic mechanism driving breast cancer

January 23, 2017
Researchers at the Wellcome Trust Sanger Institute have discovered 'hotspots' of mutations in breast cancer genomes, where mutations thought to be inactive 'passengers' in the genome have now been shown to possibly drive ...

Genomic sequence reveals new treatment options for pancreatic cancer

February 27, 2015
An international project assisted by researchers from The University of Western Australia has offered new hope to patients with pancreatic cancer.

Potential treatment for a specific kind of pancreatic cancer

September 16, 2013
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric ...

New clues to aggressive breast cancer

November 12, 2013
(Medical Xpress)—Queensland scientists have identified a genetic "switch" which indicates whether a woman's breast cancer will spread.

Gene test could pinpoint patients sensitive to new type of cancer drug

December 22, 2016
Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.